Literature DB >> 27052374

Adult ADHD: A new disease?

Gil Zalsman1,2,3, Tal Shilton1.   

Abstract

OBJECTIVES: Until recently, it was believed that attention deficit and hyperactivity disorder (ADHD) are outgrown by the end of adolescence and the beginning of adulthood. The purpose of this review is to describe the characteristics of the disease in adults, depict comorbidities that accompany it, and expand the scope over methods of diagnosis and treatment of these ages.
METHODS: A search was conducted in the PubMed/MEDLINE database for relevant key words 'ADHD', 'attention deficit', 'hyperactivity' and 'adult'. Secondary search parameters were 'comorbid', 'prevalence', 'epidemiology', 'therapy' and 'drug therapy'. Search was limited to 'English' and 'Humans'.
RESULTS: Over the years, the persistent nature of the disorder has been clarified, elucidating prevalence rate, gender differences and subtype shifts among adult ADHD population. Nevertheless, even today, there is only limited awareness of the existence of the disorder across one's lifespan, its consequences and the appropriate treatment.
CONCLUSIONS: Our results emphasise the growing awareness of adult psychosocial impairments due to ADHD symptoms and comorbidities, as well as the need for further collaboration among practitioners and mental health-care professionals to better identify the condition and allow for effective treatment.

Entities:  

Keywords:  ADHD; DSM-5; attention-deficit; diagnosis; hyperactivity

Mesh:

Year:  2016        PMID: 27052374     DOI: 10.3109/13651501.2016.1149197

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  9 in total

Review 1.  Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.

Authors:  Georgios Schoretsanitis; Jose de Leon; Chin B Eap; John M Kane; Michael Paulzen
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

Review 2.  Relationship between sex hormones, reproductive stages and ADHD: a systematic review.

Authors:  Bettina Camara; Cintia Padoin; Blanca Bolea
Journal:  Arch Womens Ment Health       Date:  2021-09-06       Impact factor: 3.633

Review 3.  Attention Deficit Hyperactivity Disorder and Substance Use Disorder: A Narrative Review.

Authors:  Bahadar S Srichawla; Chloe C Telles; Melanie Schweitzer; Bilal Darwish
Journal:  Cureus       Date:  2022-04-12

4.  Trends in attention-deficit and hyperactivity disorder (ADHD) medications among children and young adults in Ireland: a repeated cross-sectional study from 2005 to 2015.

Authors:  MaryJo Mac Avin; Mary Teeling; Kathleen E Bennett
Journal:  BMJ Open       Date:  2020-04-22       Impact factor: 2.692

5.  Development of the Korean Practice Parameter for Adult Attention-Deficit/Hyperactivity Disorder.

Authors:  Geon Ho Bahn; Young Sik Lee; Hanik K Yoo; Eui-Jung Kim; Subin Park; Doug Hyun Han; Minha Hong; Bongseog Kim; Soyoung Irene Lee; Soo Young Bhang; Seung Yup Lee; Jin Pyo Hong; Yoo-Sook Joung
Journal:  Soa Chongsonyon Chongsin Uihak       Date:  2020-01-01

6.  Dialogical Family Guidance (dfg)-Development and implementation of an intervention for families with a child with neurodevelopmental disorders.

Authors:  Diana Cavonius-Rintahaka; Anna Liisa Aho; Eva Billstedt; Christopher Gillberg
Journal:  Nurs Open       Date:  2020-09-17

Review 7.  Tryptophan modulation in individuals with attention deficit hyperactivity disorder: a systematic review.

Authors:  Larisa Maria Dinu; Nachaphol Phattharakulnij; Eleanor Jane Dommett
Journal:  J Neural Transm (Vienna)       Date:  2022-03-14       Impact factor: 3.850

8.  Social Cognition in Adult ADHD: A Systematic Review.

Authors:  Lucia Morellini; Martino Ceroni; Stefania Rossi; Giorgia Zerboni; Laura Rege-Colet; Elena Biglia; Rosalba Morese; Leonardo Sacco
Journal:  Front Psychol       Date:  2022-07-11

9.  The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.

Authors:  Thomas Grimmsmann; Wolfgang Himmel
Journal:  Eur J Clin Pharmacol       Date:  2020-08-17       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.